Our Pipeline

ITM's radiopharmaceutical pipeline is being advanced through Lumara Bio an ITM company, where we are developing a deep and robust pipeline including late-stage programs with differentiated approaches to clinically validated targets and early-stage novel programs. Our programs are designed to address a range of cancers such as neuroendocrine tumors (“NETs”), prostate cancer, glioblastomas, folate receptor α (“FRα”)-positive tumors, such as ovarian cancer, or non-small cell lung (“NSCL”) adenocarcinoma and clear-cell renal cell carcinoma (“ccRCC”).